Cerus Corporation

January 10, 2022

Forward Looking Statements & Preliminary Product Revenue Results

Except for the historical statements contained herein, this presentation contains forward-looking statements concerning Cerus' products, prospects and expected results, including statements relating to Cerus' 2022 annual product revenue guidance; Cerus' mission to make the INTERCEPT Blood System the standard of care in transfusion medicine; Cerus' ability to potentially achieve cash flow breakeven; the market opportunity for the INTERCEPT Blood System; Cerus' expectation for continued runway for revenue growth; Cerus' key 2022 priorities; [Cerus' expectations as to expanding INTERCEPT'S reach globally]; Cerus' plan to expand access to IFC across the U.S. in 2022; Cerus expectation as to continued access to capital; and other statements that are not historical fact. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not (a) meet its 2022 annual product revenue guidance, (b) effectively continue to launch and commercialize the INTERCEPT Blood System for Cryoprecipitation, (c) grow sales globally, including in its U.S. and European markets, and/or realize expected revenue contribution resulting from its U.S. and European market agreements, (d) realize meaningful and/or increasing revenue contributions from U.S. customers in the near term or at all, particularly since Cerus cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers may make under Cerus' commercial agreements with these customers, (e) effectively expand its commercialization activities into additional geographies and/or (f) realize any revenue contribution from its pipeline product candidates, whether due to Cerus' inability to obtain regulatory approval of its pipeline programs, or otherwise; risks associated with the ultimate duration and severity of the COVID-19 pandemic and resulting global economic and financial disruptions, and the current and potential future negative impacts to Cerus' business operations and financial results such as the current and potential additional disruptions to the U.S. and EMEA blood supply resulting from the evolving effects of the COVID-19 pandemic; risks associated with Cerus' lack of commercialization experience with the INTERCEPT Blood System for Cryoprecipitation and in the United States generally, and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as the resulting uncertainty of its ability to achieve market acceptance of and otherwise successfully commercialize the INTERCEPT Blood System in the United States, including as a result of licensure requirements that must be satisfied by U.S. customers prior to their engaging in interstate transport of blood components processed using the INTERCEPT Blood System; risks related to Fresenius Kabi's efforts to assure an uninterrupted supply of platelet additive solution (PAS); risks related to how any future PAS supply disruption could affect INTERCEPT's acceptance in the marketplace; risks related to how any future PAS supply disruption might affect current commercial contracts; risks related to Cerus' ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction, including IFC for the treatment and control of bleeding, and the INTERCEPT Blood System is safe, effective and economical; risks related to the uncertain and time- consuming development and regulatory process, including the risks that (a) Cerus may be unable to comply with the FDA's post-approval requirements for the INTERCEPT Blood System, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval(s) for the INTERCEPT Blood System, (b) manufacturing site Biologics License Applications necessary for Cerus to distribute the INTERCEPT Blood System for Cryoprecipitation may not be obtained in a timely manner or at all, and (c) Cerus may be unable to obtain the requisite regulatory approvals to advance its pipeline programs and bring them to market in a timely manner or at all; risks related to product safety, including the risk that the septic platelet transfusions may not be avoidable with the INTERCEPT Blood System; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or continued or more severe weakening in economic conditions resulting from the evolving effects of the COVID-19 pandemic or otherwise in the markets where Cerus currently sells and is anticipated to sell its products; Cerus' reliance on third parties to market, sell, distribute and maintain its products; Cerus' ability to maintain an effective, secure manufacturing supply chain, including the risks that (a) Cerus' supply chain could be negatively impacted as a result of the evolving effects of the COVID-19 pandemic, (b) Cerus' manufacturers could be unable to comply with extensive FDA and foreign regulatory agency requirements, and (c) Cerus may be unable to maintain its primary kit manufacturing agreement and its other supply agreements with its third party suppliers; Cerus' ability to identify and obtain additional partners to manufacture the INTERCEPT Blood System for Cryoprecipitation; risks associated with Cerus' ability to access additional funds under its term loan facility and revolving line of credit and to meet its debt service obligations, and its need for additional funding; the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of Cerus' future capital requirements and its future revenues and other financial performance and results, as well as other risks detailed in Cerus' filings with the Securities and Exchange Commission, including under the heading "Risk Factors" in Cerus' Quarterly Report on Form 10-Q, filed with the SEC on November 2, 2021, and future filings and reports by Cerus. In addition, to the extent that the COVID-19 pandemic adversely affects Cerus' business and financial results, it may also have the effect of heightening many of the other risks and uncertainties described above. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this presentation.

This presentation includes Cerus' preliminary product revenue results for the quarter and year ended December 31, 2021. Cerus is currently in the process of finalizing its full financial results for the quarter and year ended December 31, 2021, and the preliminary product revenue results presented in this presentation are based only upon preliminary information available to Cerus as of January 10, 2022. Cerus' preliminary product revenue results should not be viewed as a substitute for full audited financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Cerus' preliminary product revenue results. In addition, Cerus' independent registered public accounting firm has not audited or reviewed the preliminary product revenue results included in this presentation or expressed any opinion or other form of assurance on such preliminary product revenue results. In addition, items or events may be identified or occur after the date hereof due to the completion of operational and financial closing procedures, final audit adjustments and other developments may arise that would require Cerus to make material adjustments to the preliminary product revenue results included in this presentation. Therefore, the preliminary product revenue results included in this presentation may differ, perhaps materially, from the product revenue results that will be reflected in Cerus' audited consolidated financial statements for the year ended December 31, 2021.

Focused on Safeguarding the Blood Supply

Our Mission

To make the INTERCEPT® Blood System the **standard of care** in transfusion medicine

Our Reach

Pathogen Inactivation/Reduction **Market Leader** with ~20 years in the market

Global sales in **>40 countries**

Cumulative kit sales for **>10 million INTERCEPT treated doses** of platelets & plasma

Our Technology

INTERCEPT® Blood System

- Platelets
- Plasma
- Red Blood Cells*
- Fibrinogen Complex

**In development*

Preliminary Q4:21 and Full Year 2021 Results

Quarterly Product Revenue

Commercial Adoption Accelerating

Annual Product Revenue

2017 – 2021E CAGR >30%



Strong Q4:21 & full year 2021 results led by continued adoption of INTERCEPT Platelets in U.S.

*Q4:21 and 2021 Product Revenue and year/year growth figures are preliminary; these results have not been audited and are subject to change.

cerus

Strong Market Position on Several Fronts



Large & Growing Addressable Market Opportunity* for INTERCEPT



>$2.3B Global Market Opportunity for Current Product Portfolio Today; >$7B with addition of Red Blood Cells

Organic market growth, expansion into untapped regions and red blood cell opportunities expected to provide **continued runway for revenue growth**

*Addressable market derived from published and estimated global blood products volumes using projected average selling prices across global markets.
‡ INTERCEPT Fibrinogen Complex is currently only marketed in the U.S. and is not licensed in EMEA
^Pathogen reduced red blood cells are in development and are not currently licensed for sale in any geography.
†2021 Product revenue is preliminary; these results have not been audited and are subject to change.

cerus

2021: Accelerated U.S. INTERCEPT Platelet Adoption





Secured market leadership in U.S. market during 2021, rapidly growing product revenue and transforming our geographic mix

*2021 Product Revenue and year/year growth figures are preliminary; these results have not been audited and are subject to change.

2022: Driving Sustainable Double-Digit Growth, Led by INTERCEPT Platelets

2022 Product Revenue Guidance

$157-164 million*

+20-25% vs. 2021 preliminary revenue

Key 2022 Priorities

Extend leadership in U.S. & EMEA platelet markets



Continue initial launch of IFC across U.S.



Scaling manufacturing & supply chain

Execute on focused R&D programs

Move towards potential cashflow breakeven

*2022 Product revenue guidance provided by Cerus on and as of January 10, 2022. Actual results may differ.

cerus

Future Expansion of INTERCEPT's Global Reach

INTERCEPT Blood System for Platelets & Plasma	Extend leadership in current markets	Expand into new markets (e.g., China)	Introduce next-generation products
INTERCEPT Fibrinogen Complex	Generation of real-world outcomes data from KOLs	Penetration across the US	Targeted OUS expansion
INTERCEPT Red Blood Cells^	Completion of ongoing U.S. phase 3 clinical trials	Regulatory approvals & initial commercial launches generating real-world experience	Generating evidence with wider patient populations

^Pathogen reduced red blood cells are in development and are not currently licensed for sale in any geography

cerus

INTERCEPT Fibrinogen Complex: Initial U.S. Rollout Continues in 2022

- Approved for treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency
- First IFC revenue recognized in Q3:21
- Received New Technology Add-On Payment, effective Oct. 1, 2021
- Positive early customer experiences with IFC shared at SABM
- Plans to expand access to IFC across the U.S. in 2022 with recent BLA at Gulf Coast and commercial collaborations with BCA & OneBlood

Attractive Financial Profile

Durable Revenue Growth

>90% recurring revenue business†

Economies of Scale

Working with partners to ramp production and improve product cost profile

SG&A Leverage

Commercial infrastructure supports global market penetration

Focused R&D Investments

Robust pipeline focused on extending market leadership

Pathway to Potential Cashflow Breakeven

Demonstrating financial discipline alongside top-line growth

Strong Balance Sheet

Cash position and anticipated access to capital enables continued investment as business scales

†Recurring revenue defined as kit sales for product revenues historically

cerus



A global leader in the critical field of **blood safety and availability.**

Proprietary and proven pathogen reduction technology is an integral part of blood safety policy in the U.S. helping to potentially **create a new standard of care** in blood safety.

An industry leader with the **only FDA-approved product for pathogen reduced platelets in the U.S.**

Commercial execution delivering **double-digit top line growth**

Financially disciplined – demonstrating operating leverage on **path to potential cashflow breakeven.**

Cerus Corporation

Investor Relations

IR@cerus.com

(925) 288-6137